Merck Returns Heplisav To Dynavax After FDA Rules Vaccine Too Risky For Healthy Adults

Regulators offer option to proceed with the hepatitis B vaccine in kidney disease patients, but can the company bear the risk/cost burden of going it alone until it can repartner?